The global cardiac resynchronization therapy (CRT) market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Cardiac resynchronization therapy (CRT), or biventricular pacing, refers to a therapeutic procedure to correct or facilitate synchronized beating of the right and left ventricle of the heart. This therapy aids in improving the functioning of the heart, increasing the blood flow and facilitating faster recovery of the patient. It involves the use of a defibrillator to generate a pulse and thin insulated wires or leads to send electric impulses into the lower chambers of the heart. The device is surgically implanted and is connected to an external computer for periodic monitoring of the heart. It sends small electrical impulses to the left and right ventricles to support contraction at the same time.
The increasing prevalence of cardiovascular diseases (CVDs) across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to ailments such as arrhythmias, congenital heart disease and atrial fibrillation, is providing a thrust to the market growth. In line with this, increasing health consciousness and awareness regarding the available treatment alternatives for heart-related ailments is also contributing to the market growth. Various technological advancements, such as the development of MRI-safe and wireless CRT devices, are acting as other growth-inducing factors. These novel systems aid in optimizing CRT programming and multipoint pacing to promote the healthy activity of the heart. Other factors, including increasing healthcare expenditures capacities of the individuals, along with improvements in the healthcare infrastructure, especially in the developing nations, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cardiac resynchronization therapy (crt) market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, type, application and end user.
Breakup by Type:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Biotronik SE & Co. KG, Boston Scientific Corporation, LivaNova Plc, Medico S.p.A., Medtronic Plc, Merit Medical Systems Inc. and MicroPort Scientific Corporation.
|Base Year of the Analysis||2020|
|Segment Coverage||Type, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, Biotronik SE & Co. KG, Boston Scientific Corporation, LivaNova Plc, Medico S.p.A., Medtronic Plc, Merit Medical Systems Inc. and MicroPort Scientific Corporation|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at